If you're interested in navigating the GLP-1 generic pathway, or in developing other complex generic drug products, save the dates for our fantastic lineup of FDA/CRCG scientific workshops in 2026
ASA/AGA/ASMBS/SAGES multi-society statement (Oct 2024)
*******If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact us.
UK product information advises that patients should: Recognise symptoms of pancreatitis (severe, persistent abdominal pain radiating to the back, nausea, vomiting) Seek immediate medical attention if these symptoms develop Discontinue the medicine if pancreatitis is suspected Not restart the GLP-1 medicine if pancreatitis is confirmed Patients should also be aware of an increased risk of gallbladder disease (gallstones, cholecystitis) with GLP-1 medicines, which can present with similar abdominal symptoms and requires prompt medical attention
Weight loss typically continues for 12 to 18 months before plateauing
